Erdinç Nayır, Associate Professor of Internal Medicine and Medical Oncology at VM Medicalpark Mersin Hospital, shared a post on X:
“Phase III TRIPLETE trial:
In patients with RAS/BRAF wild-type metastatic colorectal cancer, panitumumab + modified FOLFOXIRI was compared with standard FOLFOX + panitumumab.
- Overall survival (OS) was significantly improved with the intensified regimen (≈41.1 vs ≈33.3 months; HR ≈0.79, p ≈0.049).
- No significant differences in PFS or ORR, but the OS benefit appears clinically meaningful.”
More posts on Colorectal Cancer on OncoDaily.